Stryker Corporation (NYSE:SYK) Given Consensus Recommendation of “Moderate Buy” by Analysts

Stryker Corporation (NYSE:SYK) has received an average recommendation of “Moderate Buy” from the twenty-two brokerages that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $395.0952.

SYK has been the subject of a number of analyst reports. BTIG Research cut their price target on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Wells Fargo & Company lowered their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. UBS Group dropped their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st.

Stryker Stock Performance

Shares of NYSE SYK traded up $7.18 during trading on Thursday, hitting $331.91. The company had a trading volume of 256,349 shares, compared to its average volume of 2,344,698. Stryker has a 12 month low of $281.00 and a 12 month high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The firm has a market capitalization of $127.24 billion, a P/E ratio of 38.38, a price-to-earnings-growth ratio of 2.09 and a beta of 0.77. The stock has a 50 day simple moving average of $309.80 and a 200 day simple moving average of $338.75.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.Stryker’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts anticipate that Stryker will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last 90 days. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SYK. Godfrey Financial Associates Inc. purchased a new stake in Stryker during the fourth quarter valued at $26,000. Sankala Group LLC bought a new stake in shares of Stryker in the 4th quarter worth about $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker during the 3rd quarter valued at about $27,000. Atlas Capital Advisors Inc. bought a new position in shares of Stryker in the 4th quarter valued at about $27,000. Finally, DJE Kapital AG purchased a new position in Stryker in the fourth quarter worth about $28,000. 77.09% of the stock is currently owned by institutional investors.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.